O. Alan Et Al. , "How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature," JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.26, no.4, pp.1011-1018, 2020
Alan, O. Et Al. 2020. How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature. JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.26, no.4 , 1011-1018.
Alan, O., Kuzhan, O., Koca, S., Telli, T. A., Tuylu, T. B., Ercelep, O., ... FİLİNTE, D.(2020). How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature. JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.26, no.4, 1011-1018.
Alan, Ozkan Et Al. "How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature," JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.26, no.4, 1011-1018, 2020
Alan, Ozkan Et Al. "How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature." JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.26, no.4, pp.1011-1018, 2020
Alan, O. Et Al. (2020) . "How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature." JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.26, no.4, pp.1011-1018.
@article{article, author={Ozkan Alan Et Al. }, title={How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature}, journal={JOURNAL OF ONCOLOGY PHARMACY PRACTICE}, year=2020, pages={1011-1018} }